tiprankstipranks
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
US Market
PRAX
Praxis Precision Medicines
RESEARCH TOOLSreports
Want to see PRAX full AI Analyst Report?

Praxis Precision Medicines (PRAX) Stock Forecast & Price Target

1,049 Followers
See the Price Targets and Ratings of:

PRAX Analyst Ratings

Strong Buy
18Ratings
Strong Buy
16 Buy
1 Hold
1 Sell
Based on 18 analysts giving stock ratings to
Praxis
Precision Medicines
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PRAX Stock 12 Month Forecast

Average Price Target

$633.50
▲(94.74% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Praxis Precision Medicines in the last 3 months. The average price target is $633.50 with a high forecast of $1,201.00 and a low forecast of $162.00. The average price target represents a 94.74% change from the last price of $325.30.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"$43","1202":"$1,202","332.75":"$332.8","622.5":"$622.5","912.25":"$912.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1201,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.20K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":633.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$633.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":162,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$162.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,332.75,622.5,912.25,1202],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,307.83,376.5353846153846,445.2407692307692,513.9461538461538,582.6515384615384,651.3569230769231,720.0623076923077,788.7676923076923,857.4730769230769,926.1784615384615,994.8838461538462,1063.5892307692307,1132.2946153846153,{"y":1201,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,307.83,332.88153846153847,357.9330769230769,382.9846153846154,408.03615384615387,433.0876923076923,458.1392307692308,483.1907692307692,508.2423076923077,533.2938461538462,558.3453846153845,583.396923076923,608.4484615384615,{"y":633.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,307.83,296.6123076923077,285.39461538461535,274.17692307692306,262.95923076923077,251.74153846153845,240.52384615384614,229.30615384615385,218.08846153846153,206.8707692307692,195.65307692307692,184.4353846153846,173.2176923076923,{"y":162,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.94,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.02,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.76,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.56,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":309.11,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.59,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":319.28,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":324.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.16,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":319.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":307.83,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,201Average Price Target$633.50Lowest Price Target$162.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on PRAX
Jay Olson
Oppenheimer
Oppenheimer
$650
Buy
99.82%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX) and Tonix Pharma (NASDAQ: TNXP)
Raymond James Analyst forecast on PRAX
Tiago Fauth
Raymond James
Raymond James
$765→$945
Buy
190.50%
Upside
Reiterated
08/17/26
Praxis Precision price target raised to $945 from $765 at Raymond JamesPraxis Precision price target raised to $945 from $765 at Raymond James
H.C. Wainwright Analyst forecast on PRAX
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$1,201
Buy
269.20%
Upside
Reiterated
08/10/26
H.C. Wainwright Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX)
LifeSci Capital Analyst forecast on PRAX
Francois Brisebois
LifeSci Capital
LifeSci Capital
$754
Buy
131.79%
Upside
Assigned
08/08/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX), BioCryst (NASDAQ: BCRX) and GH Research (NASDAQ: GHRS)
Piper Sandler Analyst forecast on PRAX
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$1,200
Buy
268.89%
Upside
Reiterated
08/07/26
Praxis Precision Medicines (PRAX) Gets a Buy from Piper Sandler
JonesTrading Analyst forecast on PRAX
Justin Walsh
JonesTrading
JonesTrading
$441
Buy
35.57%
Upside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Viatris (NASDAQ: VTRS), Immunocore Holdings (NASDAQ: IMCR) and Praxis Precision Medicines (NASDAQ: PRAX)
Truist Financial Analyst forecast on PRAX
Danielle Brill
Truist Financial
Truist Financial
$616
Buy
89.36%
Upside
Reiterated
08/07/26
Truist Financial Remains a Buy on Praxis Precision Medicines (PRAX)
Wells Fargo Analyst forecast on PRAX
Benjamin Burnett
Wells Fargo
Wells Fargo
$323→$362
Hold
11.28%
Upside
Reiterated
08/07/26
Praxis Precision price target raised to $362 from $323 at Wells FargoPraxis Precision price target raised to $362 from $323 at Wells Fargo
Robert W. Baird Analyst forecast on PRAX
Brian Skorney
Robert W. Baird
Robert W. Baird
$400→$514
Buy
58.01%
Upside
Reiterated
08/07/26
Praxis Precision price target raised to $514 from $400 at BairdPraxis Precision price target raised to $514 from $400 at Baird
TD Cowen Analyst forecast on PRAX
Ritu Baral
TD Cowen
TD Cowen
$510
Buy
56.78%
Upside
Reiterated
08/06/26
Praxis Precision Medicines Reaffirmed With Buy Rating on FDA Progress and $1.4 Billion Cash Runway Supporting 2028 Launch Plans
Needham Analyst forecast on PRAX
Ami Fadia
Needham
Needham
$575→$582
Buy
78.91%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (NASDAQ: TNYA), Privia Health Group (NASDAQ: PRVA) and Praxis Precision Medicines (NASDAQ: PRAX)
Guggenheim Analyst forecast on PRAX
Yatin Suneja
Guggenheim
Guggenheim
$800
Buy
145.93%
Upside
Reiterated
08/06/26
Guggenheim Keeps Their Buy Rating on Praxis Precision Medicines (PRAX)
RBC Capital Analyst forecast on PRAX
Leonid Timashev
RBC Capital
RBC Capital
$449→$462
Buy
42.02%
Upside
Assigned
08/06/26
RBC Capital Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)
Goldman Sachs Analyst forecast on PRAX
Kevin Strang
Goldman Sachs
Goldman Sachs
$447→$470
Buy
44.48%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX), Charles River Labs (NYSE: CRL) and Senseonics Holdings (NASDAQ: SENS)
Jefferies Analyst forecast on PRAX
Andrew Tsai
Jefferies
Jefferies
$550
Buy
69.07%
Upside
Reiterated
06/30/26
Jefferies Keeps Their Buy Rating on Praxis Precision Medicines (PRAX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on PRAX
Jay Olson
Oppenheimer
Oppenheimer
$650
Buy
99.82%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX) and Tonix Pharma (NASDAQ: TNXP)
Raymond James Analyst forecast on PRAX
Tiago Fauth
Raymond James
Raymond James
$765→$945
Buy
190.50%
Upside
Reiterated
08/17/26
Praxis Precision price target raised to $945 from $765 at Raymond JamesPraxis Precision price target raised to $945 from $765 at Raymond James
H.C. Wainwright Analyst forecast on PRAX
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$1,201
Buy
269.20%
Upside
Reiterated
08/10/26
H.C. Wainwright Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX)
LifeSci Capital Analyst forecast on PRAX
Francois Brisebois
LifeSci Capital
LifeSci Capital
$754
Buy
131.79%
Upside
Assigned
08/08/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX), BioCryst (NASDAQ: BCRX) and GH Research (NASDAQ: GHRS)
Piper Sandler Analyst forecast on PRAX
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$1,200
Buy
268.89%
Upside
Reiterated
08/07/26
Praxis Precision Medicines (PRAX) Gets a Buy from Piper Sandler
JonesTrading Analyst forecast on PRAX
Justin Walsh
JonesTrading
JonesTrading
$441
Buy
35.57%
Upside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Viatris (NASDAQ: VTRS), Immunocore Holdings (NASDAQ: IMCR) and Praxis Precision Medicines (NASDAQ: PRAX)
Truist Financial Analyst forecast on PRAX
Danielle Brill
Truist Financial
Truist Financial
$616
Buy
89.36%
Upside
Reiterated
08/07/26
Truist Financial Remains a Buy on Praxis Precision Medicines (PRAX)
Wells Fargo Analyst forecast on PRAX
Benjamin Burnett
Wells Fargo
Wells Fargo
$323→$362
Hold
11.28%
Upside
Reiterated
08/07/26
Praxis Precision price target raised to $362 from $323 at Wells FargoPraxis Precision price target raised to $362 from $323 at Wells Fargo
Robert W. Baird Analyst forecast on PRAX
Brian Skorney
Robert W. Baird
Robert W. Baird
$400→$514
Buy
58.01%
Upside
Reiterated
08/07/26
Praxis Precision price target raised to $514 from $400 at BairdPraxis Precision price target raised to $514 from $400 at Baird
TD Cowen Analyst forecast on PRAX
Ritu Baral
TD Cowen
TD Cowen
$510
Buy
56.78%
Upside
Reiterated
08/06/26
Praxis Precision Medicines Reaffirmed With Buy Rating on FDA Progress and $1.4 Billion Cash Runway Supporting 2028 Launch Plans
Needham Analyst forecast on PRAX
Ami Fadia
Needham
Needham
$575→$582
Buy
78.91%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (NASDAQ: TNYA), Privia Health Group (NASDAQ: PRVA) and Praxis Precision Medicines (NASDAQ: PRAX)
Guggenheim Analyst forecast on PRAX
Yatin Suneja
Guggenheim
Guggenheim
$800
Buy
145.93%
Upside
Reiterated
08/06/26
Guggenheim Keeps Their Buy Rating on Praxis Precision Medicines (PRAX)
RBC Capital Analyst forecast on PRAX
Leonid Timashev
RBC Capital
RBC Capital
$449→$462
Buy
42.02%
Upside
Assigned
08/06/26
RBC Capital Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)
Goldman Sachs Analyst forecast on PRAX
Kevin Strang
Goldman Sachs
Goldman Sachs
$447→$470
Buy
44.48%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX), Charles River Labs (NYSE: CRL) and Senseonics Holdings (NASDAQ: SENS)
Jefferies Analyst forecast on PRAX
Andrew Tsai
Jefferies
Jefferies
$550
Buy
69.07%
Upside
Reiterated
06/30/26
Jefferies Keeps Their Buy Rating on Praxis Precision Medicines (PRAX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Praxis Precision Medicines

3 Months
Yatin SunejaGuggenheim
Success Rate
14/14 ratings generated profit
100%
Average Return
+46.67%
Copying Yatin Suneja's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +46.67% per trade.
1 Year
Yatin SunejaGuggenheim
Success Rate
13/14 ratings generated profit
93%
Average Return
+182.87%
Copying Yatin Suneja's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +182.87% per trade.
2 Years
Yasmeen RahimiPiper Sandler
Success Rate
23/23 ratings generated profit
100%
Average Return
+461.07%
Copying Yasmeen Rahimi's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +461.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRAX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
28
28
45
35
32
Buy
8
6
9
8
11
Hold
4
2
4
2
3
Sell
0
1
2
2
1
Strong Sell
1
0
0
0
0
total
41
37
60
47
47
In the current month, PRAX has received 43 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. PRAX average Analyst price target in the past 3 months is 633.50.
Each month's total comprises the sum of three months' worth of ratings.

PRAX Financial Forecast

PRAX Earnings Forecast

Next quarter’s earnings estimate for PRAX is -$3.53 with a range of -$4.23 to -$2.74. The previous quarter’s EPS was -$2.87. PRAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year PRAX has Performed in-line its overall industry.
Next quarter’s earnings estimate for PRAX is -$3.53 with a range of -$4.23 to -$2.74. The previous quarter’s EPS was -$2.87. PRAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year PRAX has Performed in-line its overall industry.

PRAX Sales Forecast

Next quarter’s sales forecast for PRAX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PRAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year PRAX has Performed in-line its overall industry.
Next quarter’s sales forecast for PRAX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PRAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year PRAX has Performed in-line its overall industry.

PRAX Stock Forecast FAQ

What is PRAX’s average 12-month price target, according to analysts?
Based on analyst ratings, Praxis Precision Medicines’s 12-month average price target is 633.50.
    What is PRAX’s upside potential, based on the analysts’ average price target?
    Praxis Precision Medicines has 94.74% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PRAX a Buy, Sell or Hold?
          Praxis Precision Medicines has a consensus rating of Strong Buy which is based on 16 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Praxis Precision Medicines’s price target?
            The average price target for Praxis Precision Medicines is 633.50. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $1,201.00 ,the lowest forecast is $162.00. The average price target represents 94.74% Increase from the current price of $325.3.
              What do analysts say about Praxis Precision Medicines?
              Praxis Precision Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of PRAX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.